Belinostat is a histone deacetylase (HDAC) inhibitor used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure.
- Mechanism
- Curator reviewed
Belinostat inhibits the activity of histone deacetylase (HDAC) thus prevents the removal of acetyl groups from the lysine residues of histones and some non-histone proteins. In vitro, belinostat caused the accumulation of acetylated histones and other proteins, increased the expression of tumor-suppressor genes. It ultimately induces cell cycle arrest, inhibition of angiogenesis and/or apoptosis of some transformed cells.
- Primary indication
- Belinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with manageable safety profile.Curator reviewed · 2 structured indications
- Formula / weight
- C15H14N2O4S · 318.35 g/mol (avg)
- First approval
- United States, 2014
- Also known as
- (2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE · 2-PROPENAMIDE, N-HYDROXY-3-(3-((PHENYLAMINO)SULFONYL)PHENYL)- · 2-PROPENAMIDE, N-HYDROXY-3-(3-((PHENYLAMINO)SULFONYL)PHENYL)-, (2E)- · N-HYDROXY-3-(3-((PHENYLAMINO)SULFONYL)PHENYL)-2-PROPENAMIDE · N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
- Code names
- PX-105684 · PXD-101
- Brand names
Resolves to
NCNRHFGMJRPRSK-MDZDMXLPSA-NSMILESONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which other approved drugs treat the same conditions as Belinostat, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account